Chelly JE, et al. - In this post hoc analysis, researchers assessed the safety of hydroxypropyl-β-cyclodextrin-diclofenac (HPβCD-diclofenac) in patients aged ≥ 65 years with acute moderate-to-severe postoperative pain. Among patients aged 65–74 or ≥ 75 years and patients aged < 65 years, the reported incidence of treatment-emergent adverse events (TEAEs) was similar. Also, the groups demonstrated similar relative risks for the most frequent TEAEs, which were all similar to placebo. Varied TEAE profiles noted, all of which may be anticipated due to age-related differences in susceptibility and the types of surgery most commonly performed in each group.